Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6PBUM)

• Drug Name: Birinapant Drug Info
• Synonyms: Birinapant; 1260251-31-7; Birinapant (TL32711); TL-32711; UNII-6O4Z07B57R; TL 32711; 6O4Z07B57R; (2S)-N-[(2S)-1-[(2R,4S)-2-[[6-fluoro-2-[6-fluoro-3-[[(2R,4S)-4-hydroxy-1-[(2S)-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]pyrrolidin-2-yl]methyl]-1H-indol-2-yl]-1H-indol-3-yl]methyl]-4-hydroxypyrrolidin-1-yl]-1-oxobutan-2-yl]-2-(methylamino)propanamide

Indication

Disease Entry	ICD 11	Status	REF
Lymphoma	2A80-2A86	Phase 2	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[2]

• Cross-matching ID:
  PubChem CID: 49836020
  CAS Number: CAS 1260251-31-7
  TTD Drug ID: DM6PBUM

Molecule-Related Drug Atlas

Drug(s) Targeting X-linked inhibitor of apoptosis protein (XIAP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AT-406	DMVJW0S	Squamous head and neck cell carcinom	2D60.0	Phase 3	[4]
Phenoxodiol	DMBUJVX	Ovarian cancer	2C73	Phase 1/2	[5]
APG-1387	DMLEKUY	Haematological malignancy	2B33.Y	Phase 1	[6]
HGS-1029	DMS9WXG	Haematological malignancy	2B33.Y	Phase 1	[7]
GDC-0152	DM1B3UM	Obesity	5B81	Phase 1	[8]
PMID25980951-Compound-6	DMVSW5N	N. A.	N. A.	Patented	[9]
PMID25980951-Compound-27	DMXAH9F	N. A.	N. A.	Patented	[9]
PMID25980951-Compound-43	DMTJRCS	N. A.	N. A.	Patented	[9]
PMID25980951-Compound-1	DMYPT2H	N. A.	N. A.	Patented	[9]
PMID25980951-Compound-44	DMS5896	N. A.	N. A.	Patented	[9]

Drug(s) Targeting Cellular inhibitor of apoptosis 1 (BIRC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AT-406	DMVJW0S	Squamous head and neck cell carcinom	2D60.0	Phase 3	[4]
PMID25980951-Compound-6	DMVSW5N	N. A.	N. A.	Patented	[9]
PMID25980951-Compound-27	DMXAH9F	N. A.	N. A.	Patented	[9]
PMID25980951-Compound-43	DMTJRCS	N. A.	N. A.	Patented	[9]
PMID25980951-Compound-1	DMYPT2H	N. A.	N. A.	Patented	[9]
PMID25980951-Compound-44	DMS5896	N. A.	N. A.	Patented	[9]
PMID25980951-Compound-3	DMPSWXU	N. A.	N. A.	Patented	[9]
PMID25980951-Compound-4	DM9RZSH	N. A.	N. A.	Patented	[9]
PMID25980951-Compound-21	DMIE0MR	N. A.	N. A.	Patented	[9]
PMID25980951-Compound-42	DM8XESD	N. A.	N. A.	Patented	[9]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cellular inhibitor of apoptosis 1 (BIRC2)	TTQ5LRD	BIRC2_HUMAN	Modulator	[3]
X-linked inhibitor of apoptosis protein (XIAP)	TTR7B60	XIAP_HUMAN	Modulator	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7432).
• [2] Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.Nat Rev Drug Discov. 2016 Aug;15(8):533-50.
• [3] cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1- and RIPK3-dependent manner. Blood. 2014 Apr 17;123(16):2562-72.
• [4] Debio 1143, an antagonist of multiple inhibitor-of-apoptosis proteins, activates apoptosis and enhances radiosensitization of non-small cell lung c... Am J Cancer Res. 2014 Nov 19;4(6):943-51.
• [5] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [6] XIAP Limits Autophagic Degradation of Sox2 and Is A Therapeutic Target in Nasopharyngeal Carcinoma Stem Cells.Theranostics. 2018 Feb 5;8(6):1494-1510.
• [7] Clinical pipeline report, company report or official report of Aegera Therapeutics Inc.
• [8] Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J Med Chem. 2012 May 10;55(9):4101-13.
• [9] Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74.